Table 3.

Measures of cardiovascular autonomic function before and after treatment

	Aliskiren (n=30)^*	Placebo (n=30)^*	^**p-value
*Cardiovascular Autonomic Reflex Tests*
Mean circular resultant
Baseline	41.8±19.7	38.2±23.6
Follow-up	50.8±26.1	37.5±24.1	0.003
Expiration/inspiration ratio
Baseline	1.22±0.12	1.21±0.14
Follow-up	1.28±0.15	1.20±0.14	0.003
Valsalva ratio
Baseline	1.64±0.29	1.62±0.30 (n=29)
Follow-up	1.72±0.28	1.62±0.30 (n=28)	0.057
*Power Spectral Analysis*
Low frequency (ms²)
Baseline	338±358	674±1889
Follow-up	332±383	542±1309	0.319
High frequency (ms²)
Baseline	351±622	886±3931
Follow-up	326±679	753±3308	0.149
Low frequency/high frequency ratio
Baseline	3.0±4.5	2.0±1.7
Follow-up	3.6±4.6	2.6±2.1	0.649
Low frequency (nu)
Baseline	54±22	56±17
Follow-up	61±23	61±16	0.723
High frequency (nu)
Baseline	46±22	44±17
Follow-up	40±23	39±16	0.723
Total spectral power (ms²)
Baseline	701±902	1586±5764
Follow-up	666±907	1310±4570	0.206
*Power Spectral Analysis Coupled with Analysis of Respiratory Activity*
Respiration frequency area [RFA] (bpm²)
Baseline	2.1±2.8	3.3±12.7
Follow-up	1.9±2.4	1.8±4.7	0.314
Low frequency area [LFA] (bpm²)
Baseline	1.2±1.2	1.8±4.7
Follow-up	1.6±2.1	1.4±1.7	0.405
LFA/RFA ratio
Baseline	1.7±3.5	1.6±1.4
Follow-up	2.0±2.5	2.0±1.8	0.984

Mean±SD

sample size = 30 unless otherwise noted

^**

p-value is that of the interaction term: difference in change from baseline to follow-upbetween aliskiren and placebo.